Navigation Links
Dr. Michael Merzenich Joins Venerable Short List Honored for Cutting-Edge Neuroscientific Research
Date:10/12/2009

SAN FRANCISCO, Oct. 12 /PRNewswire/ -- Dr. Michael Merzenich, PhD - renowned neuroscientist, university professor, cochlear implant inventor, brain plasticity expert and tech entrepreneur - was formally inducted in the Institute of Medicine (IOM) today in Washington, D.C. Also a member of the National Academy of Sciences, Dr. Merzenich is one of a small group of scientists and doctors in the U.S. who have been selected for recognition by both institutions. IOM members are elected by their peers through a selective process that recognizes people who have made major contributions to the advancement of the medical sciences, health care, and public health.

"I am, of course, delighted by the generosity of my colleagues to be chosen for this honor," said Dr. Merzenich, currently co-founder and Chief Scientific Officer at Posit Science. "The discovery of the brain's ability to rewire itself has been at the core of my life's work, and I have been very fortunate to have worked with some of the brightest scientists, technologists and clinicians in the world with the mission of applying our science to improve the quality of life for others."

Dr. Merzenich is currently working with scientists and doctors at the University of California, San Francisco (UCSF) on mental health solutions, including recent promising studies on the use of brain fitness training conducted in aging, brain-injured, autistic and schizophrenic patient populations.

"Mike has been a pioneer and a leader in demonstrating that the brain function and wiring is sensitive to neural activity. His basic work has elucidated mechanisms underlying this plasticity, and his translational work has illuminated the possible ways medicine can intervene to ameliorate brain disorders," said Dr. John Rubenstein, MD, PhD, di
'/>"/>

SOURCE Posit Science
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Michael Troullis Appointed Chief Financial Officer of Quintiles Transnational Corp.
2. Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer
3. Genstar Names Michael Hurt to Its Strategic Advisory Board
4. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
5. MacroChem Announces Michael Zasloff, M.D., Ph.D. Joins Companys Scientific Advisory Board
6. Pharmasset Appoints Michael Rogers as Chief Development Officer
7. The Michael J. Fox Foundation Awards $2 Million to Shed Light on Role of LRRK2 and Alpha-Synuclein Genes in Parkinsons Disease
8. ImmunoVaccine Technologies appoints the Honourable Michael Kirby as Chair
9. Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
10. Dr Michael Rosenblatt Appointed Non-Executive Director at Shire
11. Michael D. Taylor, Ph.D., Joins Cequent Pharmaceuticals Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... --  Senomyx , Inc. (NASDAQ: SNMX ), a ... develop, and commercialize novel flavor ingredients for the food, ... for the second quarter 2015. "Moving ... track to achieve our commercial and financial goals," stated ... Company. "Since our last quarterly earnings report, our two ...
(Date:7/30/2015)... 30, 2015 HIGHLIGHTS:Q2 2015 Results ... , Reported sales were $697 million compared to ... grew organically by 8%, and changes in foreign currency ... sales by 1%. , By business unit, organic ... and 11% in SAFC Commercial. , Reported diluted ...
(Date:7/30/2015)... ... 2015 , ... GEA's Pony™ NS2006L is a ... to 1500 bar. The sanitary design gauge of the NS2006L is well suited ... Pony™ NS2006L homogenizer is an ideal solution for the processing of nanoparticles, ...
(Date:7/29/2015)... According to a new market research report, ... , published by Mordor Intelligence, the Global market is expected ... 2020, with North America being the ... global market size. The Global market for Stem Cells is ... period of (2015-2020).      (Logo: http://photos.prnewswire.com/prnh/20150428/740799) , ...
Breaking Biology Technology:SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 2Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 3
... Indevus Shares Have Been Accepted for PurchaseCHADDS FORD, ... ENDP ) announced today that, as of ... 13, 2009, approximately 71,008,964 shares (including shares delivered ... and accepted for purchase in the tender offer ...
... Personalized Medicine PortfolioNEW YORK, March 16 Samtheo ... through its subsidiary, Lyndor Biosciences LLC, with Moffitt ... small molecule that selectively inhibits the activation of ... the Akt pathway has been found to play ...
... Inc. (TSX: ONC, NASDAQ: ONCY ) announced ... available on the American Association for Cancer Research (AACR) ... website at www.oncolyticsbiotech.com . The research is scheduled ... in Denver, Colorado, April 18-22, 2009. , The first ...
Cached Biology Technology:Endo Pharmaceuticals Extends Subsequent Offering Period for Indevus Shares Until 5:00 pm EDT on Wednesday, March 18, 2009 2Endo Pharmaceuticals Extends Subsequent Offering Period for Indevus Shares Until 5:00 pm EDT on Wednesday, March 18, 2009 3Samtheo Announces License Agreement with Moffitt Cancer Center for Exclusive Rights to Novel Akt Inhibitor 2Samtheo Announces License Agreement with Moffitt Cancer Center for Exclusive Rights to Novel Akt Inhibitor 3Oncolytics Biotech(R) Inc. Announces Reovirus Research to be Presented at AACR Annual Meeting 2Oncolytics Biotech(R) Inc. Announces Reovirus Research to be Presented at AACR Annual Meeting 3
(Date:7/9/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/98rrmr/biometrics_for ... "Biometrics for Banking; Market & Technology Analysis, Adoption ... offering. The adoption for banking purposes ... the forecast is that by 2020 it will ... in delivering biometric systems to the banking industry. ...
(Date:7/8/2015)... YORK , July 8, 2015  BD (Becton, ... BD & Guidepoint Mentor, a new program ... Guidepoint,s expert network services. BD is ... to improve healthcare delivery and outcomes and, with the ... entrepreneur will be able to directly engage with industry ...
(Date:7/7/2015)... VIEW, Calif. , July 7, 2015 /PRNewswire/ ... biometrics market, Frost & Sullivan recognizes Credence ID, ... Sullivan Entrepreneurial Company of the Year Award. ... suite to aid in its mission of offering ... under-recognized populations globally. As Credence ID was formed ...
Breaking Biology News(10 mins):Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5
... gene responsible for the single most common cause of ... for the first time, a scientist told the annual ... Nice, France. Ms Melissa Thys, from the Department of ... finding may be a step towards new treatments for ...
... familiar with potato late blight, the plant disease responsible ... has the potential to be as devastating to economies ... The American Phytopathological Society (APS). , According to ... Plant Sciences Department at the University of Wyoming, Laramie, ...
... could not maintain their existence without thousands of proteins ... can cause disease, the study of protein structure and ... treatments for numerous disorders. For example, the discovery of ... development of a treatment based on insulin injections. Yet, ...
Cached Biology News:Gene responsible for common hearing loss identified for first time 2Potato wart eyed as risk to potato production 2Weizmann Institute scientists develop a general 'control switch' for protein activity 2Weizmann Institute scientists develop a general 'control switch' for protein activity 3
MDMA Mouse Monoclonal Antibody (Clone 3G8)...
... Immunogen: ... region encompassing the human, mouse, ... Accession Number: ... Assurance: Routinely evaluated by ...
... (Tyr896) Immunogen: ... acid region encompassing the human, ... Accession Number: ... Quality Assurance: Routinely evaluated ...
Mouse monoclonal [MN-8C4] to zona radiata ( Abpromise for all tested applications). Antigen: Purified eggshell proteins (zona radiata proteins and small amounts of zona pellucida proteins) from ...
Biology Products: